X
12.12 Terpenoid Alkaloids (Derived from the MEP Pathway, e.g. Aconitine) ........................... 198
12.13 Tropane-Related Alkaloids (Derived from Proline, e.g. Anatoxin A) ................................ 198
12.14 Isoxazole Alkaloids (e.g. Muscimol) .............................................................................................. 198
12.15 Muscarine ............................................................................................................................................... 198
12.16 Guanidinium Toxins (e.g. Saxitoxin) ............................................................................................. 198
12.17 Kainoids ................................................................................................................................................... 199
References ............................................................................................................................................... 199
13
Minor Groups of Secondary Metabolites ....................................................................... 205
13.1
Quinone................................................................................................................................................... 206
13.2
Polyketide (e.g. Cannabinoids) ...................................................................................................... 206
13.3
Fatty Acid-Derived Metabolites ..................................................................................................... 208
13.3.1 Polyacetylenes (e.g. Cicutoxin) ......................................................................................................... 209
13.3.2 N-Acylethanolamines .......................................................................................................................... 210
13.3.3 Alkylamides, N-acyl amides (e.g. Capsaicin) ................................................................................. 210
13.3.4 Conium Alkaloids (Pseudoalkaloids, e.g. Coniine) ..................................................................... 211
13.4
Non-protein Amino Acids ................................................................................................................. 211
13.5
Acetylcholine ........................................................................................................................................ 212
References ............................................................................................................................................... 212
Correction to: Plant-Derived Drugs Affecting GPRCs ............................................. C1
Supplementary Information
Glossary .................................................................................................................................................... 216
Contents
12.12 Terpenoid Alkaloids (Derived from the MEP Pathway, e.g. Aconitine) ........................... 198
12.13 Tropane-Related Alkaloids (Derived from Proline, e.g. Anatoxin A) ................................ 198
12.14 Isoxazole Alkaloids (e.g. Muscimol) .............................................................................................. 198
12.15 Muscarine ............................................................................................................................................... 198
12.16 Guanidinium Toxins (e.g. Saxitoxin) ............................................................................................. 198
12.17 Kainoids ................................................................................................................................................... 199
References ............................................................................................................................................... 199
13
Minor Groups of Secondary Metabolites ....................................................................... 205
13.1
Quinone................................................................................................................................................... 206
13.2
Polyketide (e.g. Cannabinoids) ...................................................................................................... 206
13.3
Fatty Acid-Derived Metabolites ..................................................................................................... 208
13.3.1 Polyacetylenes (e.g. Cicutoxin) ......................................................................................................... 209
13.3.2 N-Acylethanolamines .......................................................................................................................... 210
13.3.3 Alkylamides, N-acyl amides (e.g. Capsaicin) ................................................................................. 210
13.3.4 Conium Alkaloids (Pseudoalkaloids, e.g. Coniine) ..................................................................... 211
13.4
Non-protein Amino Acids ................................................................................................................. 211
13.5
Acetylcholine ........................................................................................................................................ 212
References ............................................................................................................................................... 212
Correction to: Plant-Derived Drugs Affecting GPRCs ............................................. C1
Supplementary Information
Glossary .................................................................................................................................................... 216
Contents